Market Overview

Regeneron's EYLEA Submitted for EU Marketing Authorization for Treatment of Macular Edema

Related REGN
Lightning Round: Jim Cramer Shares His Thoughts On GameStop, Pfizer And More
Neothetics' Fat Reduction Candidate Fails in Phase II Study
The Best- and Worst-Performing Stocks of the Last Decade (GuruFocus)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare (OTC: BAYRY) has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).

"It is our pleasure to announce the filing for EYLEA for the macular edema following CRVO indication with the European Regulatory Authority (EMA) immediately after receiving approval for the treatment of wet age-related macular degeneration.  We hope this will extend the benefits of EYLEA as a new treatment option to European patients with macular edema secondary to central retinal vein occlusion," said Kemal Malik, M.D., Head of Global Development and member of the Bayer HealthCare Executive Committee.  "With 52 weeks results of two Phase 3 trials showing substantial and sustained improvement in vision relative to the sham control group, EYLEA has the potential to provide patients and physicians a new treatment option for central retinal vein occlusion."

The submission of EYLEA for Macular Edema following CRVO is based on data from the Phase 3 COPERNICUS and GALILEO studies.  In both studies, the primary efficacy endpoint was the proportion of patients who gained

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (REGN + BAYRY)

View Comments and Join the Discussion!